Drug-induced airway diseases

Clinics in Chest Medicine

Volumn 25, Issue 1, 2004, Pages 113-122

  Babu, K Suresh ^a   Marshall, Benjamin G ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMPHOTERICIN B; ANALGESIC AGENT; ANTIINFECTIVE AGENT; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOVASCULAR AGENT; CHOLINE MAGNESIUM TRISALICYLATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IPRATROPIUM BROMIDE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYSINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROPRANOLOL; PROSTAGLANDIN E2; SALICYLAMIDE; SALICYLATE SODIUM; STEROID; TIOTROPIUM BROMIDE; UNINDEXED DRUG;

AIRWAY OBSTRUCTION; ANAPHYLAXIS; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ASTHMA; BRONCHIOLITIS; BRONCHOSPASM; CHEMORECEPTOR REFLEX; COUGHING; DEGRANULATION; DISEASE EXACERBATION; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLUSHING; FORCED EXPIRATORY VOLUME; GENOTYPE; HEART FAILURE; HUMAN; LARYNX EDEMA; LUNG FUNCTION TEST; LUNG INFLATION; LUNG TOXICITY; MEDIATOR RELEASE; MOLECULAR WEIGHT; ORBIT; PAIN; PATCH TEST; PATHOPHYSIOLOGY; PERIORBITAL EDEMA; PNEUMONIA; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; REVIEW; RHINORRHEA; SCAR FORMATION; URTICARIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARACHIDONIC ACID; ASTHMA; BRONCHIAL SPASM; BRONCHIOLITIS OBLITERANS; COUGH; HUMANS; IATROGENIC DISEASE; LUNG; OCCUPATIONAL DISEASES;

EID: 1542332723     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00136-9     Document Type: Review

References (78)

1. Leuppi JD, Schnyder P, Hartmann K, Reinhart WH, Kuhn M. Drug-induced bronchospasm: analysis of 187 spontaneously reported cases. Respiration (Herrlisheim) 2001;68(4):345-51.
2. Meeker DP, Wiedemann HP. Drug-induced bronchospasm. Clin Chest Med 1990;11(1):163-75.
3. Odeh M, Oliven A, Bassan H. Timolol eyedropinduced fatal bronchospasm in an asthmatic patient. J Fam Pract 1991;32(1):97-8.
4. Raine JM, Palazzo MG, Kerr JH, Sleight P. Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br Med J (Clin Res Ed) 1981;282(6263):548-9.
5. Fallowfield JM, Marlow HF. Propranolol is contraindicated in asthma. BMJ 1996;313(7070):1486.
6. Myers JD, Higham MA, Shakur BH, Wickremasinghe M, Ind PW. Attenuation of propranolol-induced bronchoconstriction by frusemide. Thorax 1997;52(10):861-5.
7. Trembath PW, Taylor EA, Varley J, Turner P. Effect of propranolol on the ventilatory response to hypercapnia in man. Clin Sci (Lond) 1979;57(5):465-8.
8. Mustchin CP, Gribbin HR, Tattersfield AE, George CF. Reduced respiratory responses to carbon dioxide after propranolol: a central action. BMJ 1976;2(6046):1229-31.
9. Waal-Manning HJ, Simpson FO. Practolol treatment in asthmatics. Lancet 1971;2(7736):1264-5.
10. Chang LC. Use of practolol in asthmatics: a plea for caution. Lancet 1971;2(7719):321.
11. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev 2001;(2):CD002992.
12. Bauer K, Kaik G, Kaik B. Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. Hypertension 1994;24(3):339-46.
13. Spector SL, Wangaard CH, Farr RS. Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 1979;64(6 Pt 1):500-6.
14. Sturtevant J. NSAID-induced bronchospasm - a common and serious problem. A report from MEDSAFE, the New Zealand medicines and medical devices safety authority. N Z Dent J 1999;95(421):84.
15. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28(4):717-22.
16. Holgate ST, Burns GB, Robinson C, Church MK. Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol 1984;133(4):2138-44.
17. Churchill L, Chilton FH, Resau JH, Bascom R, Hubbard WC, Proud D. Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells. Am Rev Respir Dis 1989;140(2):449-59.
18. Subratty AH, Hooloman NK. Role of circulating inflammatory cytokines in patients during an acute attack of bronchial asthma. Indian J Chest Dis Allied Sci 1998;40(1):17-21.
19. Stringer B, Kobzik L. Alveolar macrophage uptake of the environmental particulate titanium dioxide: role of surfactant components.AmJ Respir Cell Mol Biol 1996;14(2):155-60.
20. Stuhrmann M, Bohnhorst B, Peters U, Bohle RM, Poets CF, Schmidtke J. Prenatal diagnosis of congenital alveolar proteinosis (surfactant protein B deficiency). Prenatal Diagn 1998;18(9):953-5.
21. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144(4):957-8.
22. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101(4):834-46.
23. Babu KS, Salvi SS. Aspirin and asthma. Chest 2000;118(5):1470-6.
24. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. Prevalence of crosssensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96(4):480-5.
25. Bianco S, Robuschi M, Petrigni G, Scuri M, Pieroni MG, Refini RM, et al. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993;46(Suppl 1):115-20.
26. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998;53(12):1231-3.
27. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001;119(5):1533-46.
28. Szczeklik A, Dworski R, Mastalerz L, Prokop A, Sheller JR, Nizankowska E, et al. Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. Am J Respir Crit Care Med 1998;158(4):1168-72.
29. Schaefer OP, Gore JM. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology 1999;91(1):8-13.
30. Wilkinson JR, Roberts JA, Bradding P, Holgate ST, Howarth PH. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ 1992;305(6859):931-2.
31. Asmus MJ, Sherman J, Hendeles L. Bronchoconstrictor additives in bronchodilator solutions. J Allergy Clin Immunol 1999;104(2 Pt 2):S53-60.
32. Mant TG, Tempowski JH, Volans GN, Talbot JC. Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed) 1984;289(6439):217-9.
33. Shelton MJ, Minor JR. Aerosolized pentamidine in AIDS patients with asthma. Am J Hosp Pharm 1991;48(3):556-7.
34. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, Sluiter WJ, Daenen SM, de Pauw B, et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997;16(5):364-8.
35. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316(26):1627-32.
36. Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol 2001;11(7):1267-75.
37. Morcos SK. Review article: effects of radiographic contrast media on the lung. Br J Radiol 2003;76(905):290-5.
38. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12(12):2654-66.
39. Laxenaire MC. [Epidemiology of anesthetic anaphylactoid reactions. Fourth multicenter survey (July 1994-December 1996)]. Ann Fr Anesth Reanim 1999;18(7):796-809 [in French].
40. International Rheumatic Fever Study Group. Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. Lancet 1991;337(8753):1308-10.
41. Laxenaire MC. [Substances responsible for peranesthetic anaphylactic shock. A third French multicenter study (1992-94)]. Ann Fr Anesth Reanim 1996;15(8):1211-8 [in French].
42. Asik I, Goktug A, Gulay I, Alkis N, Uysalel A. Comparison of bupivacaine 0.2% and ropivacaine 0.2% combined with fentanyl for epidural analgesia during labour. Eur J Anaesthesiol 2002;19(4):263-70.
43. Gruchalla RS. Drug metabolism, danger signals, and drug-induced hypersensitivity. J Allergy Clin Immunol 2001;108(4):475-88.
44. Moneret-Vautrin DA, Gueant JL, Kamel L, Laxenaire MC, el Kholty S, Nicolas JP. Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases. J Allergy Clin Immunol 1988;82(5 Pt 1):745-52.
45. Porri F, Lemiere C, Birnbaum J, Guilloux L, Lanteaume A, Didelot R, et al. Prevalence of muscle relaxant sensitivity in a general population: implications for a preoperative screening. Clin Exp Allergy 1999;29(1):72-5.
46. Porri F, Lemiere C, Birnbaum J, Guilloux L, Lanteaume A, Didelot R, et al. Prevalence of latex sensitization in subjects attending health screening: implications for a perioperative screening. Clin Exp Allergy 1997;27(4):413-7.
47. Mertes PM, Laxenaire MC. Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol 2002;19(4):240-62.
48. Chamberlain D. Emergency medical treatment of anaphylactic reactions. Project Team of the Resuscitation Council (UK). J Accid Emerg Med 1999;16(4):243-7.
49. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000;30(8):1144-50.
50. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994;21(5)(Suppl 10):42-46 [discussion 46-7].
51. Israel RH, Olson JP. Pulmonary edema associated with intravenous vinblastine. JAMA 1978;240(15):1585.
52. Konits PH, Aisner J, Sutherland JC, Wiernik PH. Possible pulmonary toxicity secondary to vinblastine. Cancer 1982;50(12):2771-4.
53. Kris MG, Pablo D, Gralla RJ, Burke MT, Prestifilippo J, Lewin D. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy. Cancer Treat Rep 1984;68(7-8):1029-31.
54. Bohrer H, Fleischer F, Werning P. Tussive effect of a fentanyl bolus administered through a central venous catheter. Anaesthesia 1990;45(1):18-21.
55. Agarwal A, Azim A, Ambesh S, Bose N, Dhiraj S, Sahu D, et al. Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl. Can J Anaesth 2003;50(3):297-300.
56. Schnabel A, Dalhoff K, Bauerfeind S, Barth J, Gross WL. Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 1996;15(3):277-82.
57. Mitra S, Sinha PK, Anand LK, Gombar KK. Propofol-induced violent coughing. Anaesthesia 2000;55(7):707-8.
58. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117(3):234-42.
59. Olsen CG. Delay of diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor-induced cough in office practice. Arch Fam Med 1995;4(6):525-8.
60. Lalloo UG, Barnes PJ, Chung KF. Pathophysiology and clinical presentations of cough. J Allergy Clin Immunol 1996;98(5)(Pt 2):S91-6 [discussion S96-7].
61. Ravid D, Lishner M, Lang R, Ravid M. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. J Clin Pharmacol 1994;34(11):1116-20.
62. Fuller RW, Choudry NB. Increased cough reflex associated with angiotensin converting enzyme inhibitor therapy. BMJ 1987;16:1432-3.
63. Gannon TH, Eby TL. Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction. Laryngoscope 1990;100(11):1156-60.
64. Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis 1987;135(1):176-80.
65. Umemura K, Nakashima M, Saruta T. Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors. Life Sci 1997;60(18):1583-8.
66. Malini PL, Strocchi E, Zanardi M, Milani M, Ambrosioni E. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet 1997;350(9070):15-8.
67. Luque CA, Vazquez Ortiz M. Treatment of ACE inhibitor-induced cough. Pharmacotherapy 1999;19(7): 804-10.
68. Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, et al. Association of polymorphisms of the reninangiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002;16(12):857-63.
69. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. Br Med J (Clin Res Ed) 1987;294(6586):1521-3.
70. Hume AL, Murphy JL, Lauerman SE. Angiotensin-converting enzyme inhibitor-induced cough. Pharmacotherapy 1989;9(2):88-90.
71. Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough. Lancet 1995;345(8941):13-6.
72. Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med 2001;161(2):158-64.
73. Colby TV. Bronchiolitis. Pathologic considerations. Am J Clin Pathol 1998;109(1):101-9.
74. McAdams AJ. Bronchiolitis obliterans. Am J Med 1955;19:314.
75. Turner-Warwick M. Adverse reactions affecting the lung: possible association with D-penicillamine. J Rheumatol Suppl 1981;7:166-8.
76. Stein HB, Patterson AC, Offer RC, Atkins CJ, Teufel A, Robinson HS. Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med 1980;92(1):24-9.
77. Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest 1982;81(6):766-8.
78. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine 1993;72:151-83.